##  [Pulse updates](/news/newsroom/pulse-updates "Pulse updates") 

  

 

 Date Range 

 





 Language- Any -EnglishGermanFrench

 

 Start Date

 

 End Date

 

 

 

 

Showing 21 results 

## January 2025

- [ Pulse Update Jan 14, 2025 Novartis presentation at J.P. Morgan Healthcare Conference 2025 
    
    
    
    
    
     ](/news/novartis-presentation-jp-morgan-healthcare-conference-2025)
 


## December 2024

- [ Pulse Update Dec 02, 2024 Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease 
    
    
    
    
    
     ](/news/novartis-bolsters-neuroscience-pipeline-licensing-ptc518-huntingtons-disease)
 


## May 2024

- [ Pulse Update May 10, 2024 Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML 
    
    
    
    
    
     ](/news/novartis-receives-fda-breakthrough-therapy-designation-scemblix-1l-cml)
 


## April 2024

- [ Pulse Update Apr 09, 2024 Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 
    
    
    
    
    
     ](/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2)
- [ Pulse Update Apr 04, 2024 Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study 
    
    
    
    
    
     ](/news/novartis-confirms-plans-file-pluvicto-pre-taxane-label-expansion-h2-2024-based-latest-data-from-phase-iii-psmafore-study)
 


## February 2024

- [ Pulse Update Feb 16, 2024 Novartis appoints Sloan Simpson as Global Head of Investor Relations 
    
    
    
    
    
     ](/news/novartis-appoints-sloan-simpson-global-head-investor-relations)
 


## January 2024

- [ Pulse Update Jan 08, 2024 Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024 
    
    
    
    
    
     ](/news/novartis-shares-strategy-and-growth-update-jp-morgan-healthcare-conference-2024)
 


## April 2023

- [ Pulse Update Apr 21, 2023 FDA approves Novartis Millburn facility for US commercial production of Pluvicto® 
    
    
    
    
    
     ](/news/fda-approves-novartis-millburn-facility-us-commercial-production-pluvicto)
 


## March 2023

- [ Pulse Update Mar 02, 2023 Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch 
    
    
    
    
    
     ](/news/novartis-completes-fda-filing-approval-millburn-facility-support-pluvicto-launch)
 


## January 2023

- [ Pulse Update Jan 09, 2023 Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023 
    
    
    
    
    
     ](/news/novartis-shares-strategy-insights-and-highlights-key-pipeline-catalysts-jp-morgan-healthcare-conference-2023)
 


## December 2021

- [ Pulse Update Dec 16, 2021 Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease 
    
    
    
    
    
     ](/news/novartis-receives-fda-fast-track-designation-branaplam-lmi070-treatment-huntingtons-disease)
 


## September 2021

- [ Pulse Update Sep 28, 2021 FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC) 
    
    
    
    
    
     ](/news/fda-grants-priority-review-investigational-targeted-radioligand-therapy-177lu-psma-617-patients-metastatic-castration-resistant-prostate-cancer-mcrpc)
 


 

 #### Pagination

- <a class="page-link btn disabled" href="" rel="prev" title="Go to previous page"> ‹ Previous page </a>
- <a class="page-link" href="" title="page 1 active out of 2 pages">  1  </a>
- [2](?page=1 "page 2  out of 2 pages")
- [ › Next page ](?page=1 "Go to next page")
-